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012.12.00Abstract Aim of the work: This study aimed to investigate serum levels of vascular endothelial
growth factor (VEGF) and to measure common carotid intima media thickness (cc-IMT) in Egyp-
tian patients with Behc¸et’s disease (BD) to evaluate their relations to disease activity and different
clinical manifestations.
Patients and methods: Seventy patients with BD and 70 healthy controls participated in this
study. Behc¸et’s disease patients were subjected to detailed history taking, thorough clinical exami-
nation, disease activity assessment using the BD Current Activity Form (BDCAF) and laboratory
investigation. Vascular endothelial growth factor levels were measured using ELISA. The carotid
arteries were assessed for cc-IMT and plaques with a carotid high-resolution B-mode ultrasound.artment of Rheumatology &
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88 S.S. Ganeb et al.Results: The mean cc-IMT showed a signiﬁcant difference in BD patients compared to controls
(p< 0.011). Three BD patients had plaques (4.3%). There were signiﬁcant correlations of cc-IMT
with disease duration (p< 0.001), systolic blood pressure (BP) (p= 0.029), diastolic BP
(p= 0.041), total cholesterol (p< 0.001) and LDL (p< 0.001) and insigniﬁcant correlation with
BDCAF (p= 0.054). There was a signiﬁcant elevation of VEGF levels (p< 0.001) in BD patients
compared to controls. VEGF levels showed signiﬁcant correlations with ESR (p= 0.14), CRP
(p< 0.001) and BDCAF (P= 0.02), while there was an insigniﬁcant correlation with cc-IMT
(p= 0.107).
Conclusion: BD patients have ultrasonographic evidence of subclinical atherosclerosis which was
associated with increasing age, longer disease duration, elevated systolic and diastolic BP, total cho-
lesterol and LDL. Elevated VEGF showed statistically signiﬁcant positive correlations with
BDCAF and thus can be used as a marker of disease activity and/or therapeutic targets in BD
patients.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Behc¸et’s disease is a systemic vasculitis of unknown origin,
characterized by recurrent oral and genital ulcers, uveitis, vas-
cular manifestations and other multisystem affections [1,2].
Vasculitis causes endothelial destruction and thrombosis [3].
Inﬂammatory thrombosis is well-known in BD [4]. It has been
recognized that vascular endothelial dysfunction occurs in BD
and plays a substantial role in the vascular lesions. The path-
ogenic mechanism is uncertain [5].
There are several identiﬁed vascular endothelial growth
factor (VEGF) family members: VEGF (VEGF-A), VEGF-B,
VEGF-C, VEGF-D and placenta growth factor which are
key regulators of physiological and pathological vasculogene-
sis, angiogenesis, lymphangiogenesis, hematopoiesis and vascu-
lar permeability. VEGF is essential for angiogenesis and
inﬂammation that are pathophysiologic factors of BD [6].
Vascular endothelial growth factor (VEGF) is a potent
cytokine that modulates angiogenesis and vasculogenesis by
acting as an essential mitogen for vascular endothelial
cells [7]. It is an important factor in the progression of
atherosclerosis [8].
Common carotid intima-media thickness is an endothelial
cell dysfunction parameter that may be associated with athero-
sclerosis [9]. Its thickness is a known good predictor of cardio-
vascular accidents in the general population [10] and has been
reported in the patients with different rheumatic diseases as a
strong predictor of cardiovascular events [11]. The carotid ar-
tery can be studied by B-mode Doppler ultrasound which
shows the carotid artery intima and media width that can be
visualized in all subjects [12].
Primary and secondary prevention of life-threatening
thrombocoagulopathy in BD is a complex process.
Aneurysmatic, pseudoaneurysmatic and thrombotic affections
of large- and medium-size arteries and right-sided intracardiac
thrombotic masses have been reported [13]. Atherosclerosis
may develop during the course of BD [9]. Increased
atherosclerotic changes may cause increased carotid IMT in
BD [14].
The aim of this study was to investigate serum levels of
VEGF and to measure the cc-IMT in Egyptian patients with
BD to evaluate their relations to disease activity and different
clinical manifestations.2. Patients and methods
2.1. Subjects
Seventy patients diagnosed as BD according to the Interna-
tional Study Group criteria (ISGC, 1990) [15] and 70 age
and sex matched healthy volunteers serving as control group
were enrolled into this study. This study was carried out be-
tween July 2010 and June 2011 and the patients were recruited
and selected from inpatient and outpatient clinics of Rheuma-
tology, Rehabilitation & Physical Medicine, General Medi-
cine, Ophthalmology and Dermatology & Andrology of
Benha University hospitals.
Exclusion criteria: patients were excluded from the study if
they had other illnesses that might affect the results of the
study (or are risk factor for atherosclerosis) such as diabetes
mellitus or hypertension, hyperlipidemia, alcoholics, smokers,
family history of atherosclerosis, manifest cardiac diseases
(infarction, stent or coronary bypass), cerebrovascular events
or the statin therapy as well as patients with other rheumato-
logical diseases.
The local Ethics Committee of our institute approved the
study and informed written consents were obtained from all
participants.
2.2. Clinical assessments
All BD patients were subjected to the following:
- Detailed history taking.
- Thorough clinical examination with stress on dermatologi-
cal, locomotor, vascular and ophthalmologic examination
and skin pathergy test [16].
- Assessment of disease activity according to Behc¸et’s Dis-
ease Current Activity Form (BDCAF) score [17].
- All manifestations at the time of study or during the month
before the study were considered.2.3. Biochemical assessments
- Laboratory investigations: venous blood samples were
obtained from all patients and the control group: after
Vascular endothelial growth factor and subclinical atherosclerosis 8912 h fast. Samples were collected in serum separator tubes,
allowed to clot for 30 min and centrifuged for 15 min at
2000g at room temperature; serum samples were collected
and stored at –20 C until analyzed.
- One ml blood on EDTA was used for complete blood pic-
ture by sysmex Kx-21.
- Erythrocyte sedimentation rate (ESR): 1.6 ml blood on
0.4Na citrate to be measured by the Westergren method
recorded in mm/hr [18].
- Three ml of blood was put in a plain tube to separate serum
for measuring C-reactive protein (CRP) by turbidity assay
against control as speciﬁed by the manufacturer (Turbox,
Orion diagnostica, Cat. No. 67559) [19]. Fasting and post-
prandial blood sugar (PP bl. S) and lipid proﬁle, total cho-
lesterol, low density lipoprotein (LDL), high density
lipoprotein (HDL) and Triglyceride (TG) were measured
by Hitachi autoanalyser.
- VEGF levels in the serum were measured by enzyme-linked
immunosorbent assay (ELISA) using microtiter plates
coated by anti-human VEGF antibody (R&D systems, Min-
neapolis, MN) and the buffer was sodium carbonate. The
plate was incubated with 0.2 ng/ml biotinylated goat antihu-
manVEGF. The enzyme usedwas peroxidase. The color was
induced by TMB/H2O2 substrate and the reaction stopped
by I M phosphoric acid. Concentrations were expressed in
pg/ml after optical density determination at 450 nm. The
detection limit of the VEGF assay was 9.0 pg/ml.2.4. Radiological examination
- High-resolution B-mode Doppler ultrasound examination:
patients and controls underwent extracranial carotid arter-
ies assessment by high resolution B-mode ultrasound in the
Radiodiagnosis Department, Benha University Hospitals.
The ultrasonographic scan protocol was performed on the
last two centimeters of both common carotid arteries, prior
to its bifurcation, by using TOSHIBA 526 – DEVICE
equipped with 10 MHz imaging transducer to measure
intima-media thickness in the common carotid artery (cc-
IMT) in mm and detect the presence of atheromatous pla-
ques. The measurement was repeated three times on each
side (right and left) and the mean of the six measurements
was used for this study. Plaques were deﬁned as a distinct
area protruding into the vessel lumen with at least 50%
greater thickness than the surrounding areas.Table 1 Clinical manifestations present at the time of study or
during the month before the study of BD patients (n= 70).Statistical analysis: The program used was SPSS version 16.
Quantitative data were analyzed using mean and standard
deviation while frequency and percentage were used with qual-
itative data. Student’s t test was used to compare means of dif-
ferent groups while chi square (x2) to compare frequencies.
Pearson correlation was used to ﬁnd relationships between
variables (r). A p value of <0.05 was considered to be
signiﬁcant.No. of patients Percentage (%)
Oral aphthous ulcers 47 67.1
Genital ulcers 16 22.9
Skin lesions 33 47.1
Arthritis 33 47.1
Ocular manifestations 26 37.1
Vascular lesions 12 17.1
+ve skin Pathergy test 19 27.13. Results
This study included 70 patients: 43 males (61.4%) and 27 fe-
males (38.6%). Their ages ranged from 22–46 years with a
mean of 32.84 ± 3.63 years. Age and sex matched 70 healthy
volunteers, as a control group [41 males (58.6%) and 29females (41.4%)], aged from 21–48 years with a mean of
32.81 ± 3.89 years were also included. Patients’ disease dura-
tion ranged from 2 to 12 years with a mean of
6.74 ± 2.16 years. There were 12 patients (17.1%) with vascu-
lar lesions: 10 had deep-vein thrombosis, one with pulmonary
embolism and one had retinopathy. The mean BDCAF scores
were 4.7 ± 4.2.
One patient (1.4%) was on steroid use of 20 mg/d for the
last one month. Thirty-one (44.3%) patients were on the col-
chicine therapy (ranging between 1 and 1.5 mg/d), 11
(15.7%) were also on NSAIDs together with colchicine and
two (2.9%) of them were taking low-dose steroids along with
colchicine. Twenty-seven (38.6%) patients were on NSAIDs
only. None of the patients were on the statin therapy.
Clinical manifestations, descriptive and laboratory data of
BD patients and the control group are shown in (Tables 1
and 2). Serum levels of VEGF were signiﬁcantly higher
(t= 21.94, p< 0.001) in BD patients in comparison to the
control group.
A statistically signiﬁcant elevation of VEGF serum levels
was observed in BD patients with skin lesions (t= 6.25,
p< 0.001), arthritis (t= 7.42, p< 0.001), ocular lesions
(t= 8.52, p< 0.001) and vascular lesions (t= 9.3,
p< 0.001), while there was an insigniﬁcant increase of serum
VEGF levels in patients with oral ulcers (t= 0.58, p= 0.56),
genital ulcers (t= 0.98, p= 0.33) or a positive skin Pathergy
test (t= 1.63, P= 0.107) (Table 3).
In the ultrasound study of the common carotid artery, the
mean cc-IMT in BD patients and controls was 0.67 ± 0.25
and 0.57 ± 0.15 mm, respectively with a statistically signiﬁ-
cant difference (p< 0.011) between both groups. Three BD
patients (4.3%) had plaques while none of the controls had
plaques and the difference was statistically insigniﬁcant
(x2 = 1.36, p= 0.24) (Table 4). Ultrasonographic ﬁndings of
the common carotid artery are shown in (Fig. 1): (a)-Normal
common carotid intima media thickness (cc-IMT) in a BD pa-
tient measures 0.6 mm. (b)-Increased cc-IMT in a BD patient
measures 1.3 mm. (c)-A plaque is seen at the medial wall of
the right common carotid artery in a BD patient which mea-
sures 4 · 1.5 mm at maximum dimensions.
A statistically signiﬁcant increase of cc-IMT was observed
in BD patients with ocular lesions (t= 4.41, p< 0.001) and
vascular lesions (t= 3.57, p< 0.001), while there was an
insigniﬁcant increase of cc-IMT in patients with oral ulcers
(t= 1.73, p= 0.09), genital ulcers (t= 1.92, p= 0.06) skin le-
sions (t= 0.41, p= 0.69), arthritis (t= 0.7, p= 0.49) or a
positive skin Pathergy test (t= 0.5, P= 0.62) (Table 5).
Table 3 Comparison between VEGF serum levels in BD patients according to different clinical manifestations (n= 70).
Variable Mean VEGF Pg/ml
Patients with Patients without t p
Oral ulcers (n= 47) 256.13 ± 93.53 242.22 ± 95.34 0.58 0.56
Genital ulcers (n= 16) 266.69 ± 78.18 244.72 ± 79.07 0.98 0.33
Skin lesions (n= 33) 296.09 ± 47.42 196.46 ± 79.84 6.25 0.001a
Arthritis (n= 33) 321.97 ± 89.71 198.24 ± 44.83 7.42 0.001a
Ocular lesions (n= 26) 325.96 ± 90.25 189.2 ± 43.92 8.52 0.001a
Vascular lesions (n= 12) 351.08 ± 93.25 176.57 ± 49.99 9.3 0.001a
+ve Pathergy (n= 19) 249.63 ± 73.54 221.08 ± 61.81a 1.63 0.107
a p< 0.05 = signiﬁcant, p> 0.05 = non signiﬁcant.
Table 2 Comparison of clinical and laboratory data between BD patients and the control group.
Parameters Patients
mean ± SD
n= 70
Controls
mean ± SD
n= 70
t p
Age (yrs) 32.84 ± 3.63 32.81 ± 3.89 0.045 0.96
Disease duration (yrs) 6.74 ± 2.16 – – –
Body mass index 29.27 ± 6.72 28.4 ± 6.03 0.803 0.423
Systolic blood pressure (mmHg) 124.47 ± 7.92 120.04 ± 9.2 1.7 0.09
Diastolic blood pressure (mmHg) 80.96 ± 4.21 79.8 ± 3.91 1.68 0.094
ESR (mm/hr) 36.56 ± 4.27 14.51 ± 3.09 35.021 0.001*
CRP (mg/dl) 11.98 ± 9.54 5.13 ± 3.93 5.554 0.001*
Fasting bl. sugar (mg/dl) 101.39 ± 14.42 105.81 ± 13.84 1.8 0.06
PP bl. sugar (mg/dl) 150.01 ± 15.63 146.79 ± 7.49 1.6 0.12
LDL(mg/dl) 104.17 ± 22.97 97.8 ± 22.24 1.67 0.098
HDL(mg/dl) 55.79 ± 19.73 58.63 ± 18.45 0.881 0.38
TG(mg/dl) 131.86 ± 25.26 126.9 ± 29.9 1.06 0.29
Cholesterol (mg/dl) 198.54 ± 28.74 190.87 ± 25.34 1.68 0.096
VEGF pg/ml 257.36 ± 74.24 59.39 ± 13.76 21.94 0.001*
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, PP bl. S: postprandial blood sugar, LDL: low density lipoprotein, HDL: high
density lipoprotein, TG: triglyceride, VEGF: vascular endothelial growth factor.
* p < 0.05 = signiﬁcant, p> 0.05 = not signiﬁcant values are expressed in mean ± SD.
Table 4 B-mode ultrasound study of the common carotid artery in BD patients (n= 70) and controls (n= 70).
Patients Controls Test of signiﬁcance p
cc-IMT (mean ± SD/mm) 0.67 ± 0.25 0.57 ± 0.15 t= 2.59 0.011a
Plaques (no/%) No 3 No 0 x2 = 1.36 0.243
% 4.3 % 00
x2 = chi-square. cc-IMT: common carotid intima media thickness.
a p< 0.05 = signiﬁcant, p> 0.05 = insigniﬁcant.
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among BD patients, they were found to have statistically sig-
niﬁcant positive correlations with ESR (r= 0.29, p= 0.14),
CRP (r= 0.89, p< 0.001) and BDCAF (r= 0.278,
p= 0.02) (Fig. 2). Correlating cc-IMT with different disease
variables, statistically signiﬁcant correlations were found with
age (r= 0.51, p< 0.001), disease duration (r= 0.51,
p< 0.001), systolic blood pressure (r= 0.26, p= 0.03), dia-
stolic blood pressure (r= 0.24, p= 0.04), total cholesterol
(r= 0.46, p< 0.001) and LDL (r= 0.49, p< 0.001) and an
insigniﬁcant correlation was found with BDCAF (r= 0.23,p= 0.05) (Table 6). An insigniﬁcant correlation was observed
between cc-IMT and serum VEGF levels (r= 0.194,
p= 0.107) (Fig. 3).4. Discussion
Behc¸et’s disease is a systemic immune-inﬂammatory vasculitic
disease with endothelial dysfunction [20]. All types and sizes of
blood vessels can be affected [9]. Systemic vasculitis and endo-
thelial dysfunction are the main features of BD inﬂammatory
(a) (b) (c)
Figure 1 (a)-Normal common carotid intima media thickness (cc-IMT) in a Behc¸et’s disease patient as revealed by ultrasonography
measures 0.6 mm. (b)-Increased common carotid intima media thickness in a Behc¸et’s disease patient as revealed by ultrasonography
measures 1.3 mm. (c)-A plaque is seen at the medial wall of the right common carotid artery in a Behc¸et’s disease patient as revealed by
ultrasonography measures 4 · 1.5 mm at maximum dimensions.
Table 5 Comparison between cc-IMT in BD patients according to different clinical manifestations (n= 70).
Variable Mean cc-IMT/mm
Patients With Patients Without t P
Oral ulcers (n= 47) 0.70 ± 0.23 0.60 ± 0.22 1.729 0.088
Genital ulcers (n= 16) 0.76 ± 0.21 0.64 ± 0.22 1.919 0.059
Skin lesions (n= 33) 0.68 ± 0.21 0.67 ± 0.19 0.406 0.686
Arthritis (n= 33) 0.69 ± 0.20 0.66 ± 0.19 0.70 0.487
Ocular lesions (n= 26) 0.78 ± 0.17 0.61 ± 0.16 4.41 0.001a
Vascular lesions (n= 12) 0.83 ± 0.124 0.64 ± 0.174 3.57 0.001a
+ve Pathergy (n= 19) 0.69 ± 0.227 0.66 ± 0.233 0.495 0.622
a p< 0.05 = signiﬁcant, p> 0.05 = non signiﬁcant.
Figure 2 Correlation between vascular endothelial growth factor (VEGF) serum levels with Behc¸et’s Disease Current Activity Form
(BDCAF) (r= 0.278, p= 0.02* signiﬁcant).
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Table 6 Correlations of cc-IMT in BD patients with age,
disease duration, BDCAF, ESR, risk factors for atherosclerosis
and VEGF.
Parameters r p
Age (yrs) 0.512 0.000a
Disease duration (yrs) 0.511 0.000a
Body mass index 0.075 0.537
Systolic blood pressure (mmHg) 0.261 0.029a
Diastolic blood pressure (mmHg) 0.244 0.041a
BDCAF 0.232 0.054
ESR (mm/hr) 0.135 0.263
CRP(mg/dl) 0.191 0.113
Fasting bl. sugar (mg/dl) 0.070 0.563
PP bl. sugar (mg/dl) 0.223 0.063
LDL(mg/dl) 0.491 0.000a
HDL (mg/dl) 0.222 0.065
TG (mg/dl) 0.150 0.215
Cholesterol(mg/dl) 0.463 0.000
VEGF pg/ml 0.194 0.107
BDCAF: Behc¸et’s Disease Current Activity Form, ESR: erythro-
cyte sedimentation rate, CRP: C-reactive protein, PP bl. S: post-
prandial blood sugar, LDL: low density lipoprotein, HDL: high
density lipoprotein, TG: triglyceride, VEGF: vascular endothelial
growth factor.
a p< 0.05 = signiﬁcant, p> 0.05 = not signiﬁcant.
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we aimed to investigate serum levels of VEGF and to measure
cc-IMT in Egyptian patients with BD to evaluate their rela-
tions to disease activity and different clinical manifestations.
This study demonstrated that serum levels of VEGF were
signiﬁcantly increased in BD patients compared to healthy
controls (p< 0.001). This was consistent with the results of
previous reports [22–25]. The mechanism of increased serum
VEGF levels and its mode of action may be explained as fol-Figure 3 Correlation between common carotid intima media thickne
levels (r= 0.194, p= 0.107). p> 0.05 = not signiﬁcant.lows: endothelial cells have a special importance among the
cells that secrete VEGF [26,6]. In vasculitis, inﬂammation
stimulates the expression of VEGF which leads to the forma-
tion of new capillary networks [27].
In our study a signiﬁcant elevation of VEGF serum levels in
BD patients with skin lesions (p< 0.001) and with ocular
manifestations (p< 0.001) was observed. Shaker et al. [25] re-
vealed elevation of VEGF serum levels in BD patients with
ocular manifestations [25]. Kamoun et al. [6] stated that ele-
vated serum levels of VEGF in BD patients with ocular lesions
propose a central role for VEGF in ocular events in BD. More-
over, Scaria and his colleagues [28] supported the theory of in-
creased formation of VEGF by retinal cells and its pivotal role
in ocular neovascularization. In contrast to our study, Bozoglu
et al. [22] found no signiﬁcant differences of VEGF serum lev-
els in BD patients with skin lesions. Signiﬁcant elevation of
VEGF serum levels with clinical vascular lesions was found
in this study (p< 0.001). This conﬁrms the previous studies
[22,25].
We found signiﬁcant positive correlations of VEGF serum
levels with ESR and CRP while Bozoglu et al. [22] revealed
that serum VEGF levels did not correlate with either ESR or
CRP. Also there was a signiﬁcant positive correlation of
VEGF serum levels with BDCAF (p= 0.02). C¸ekmen et al.
[29] found signiﬁcantly higher VEGF serum levels in BD pa-
tients with active disease and stated that elevated serum levels
VEGF can be considered a disease activity marker that may be
related to endothelial dysfunction essential in the etiopatho-
genesis of BD. In addition, Yalc¸in et al. [23] found over-
expression of VEGF in their study on BD patients and sug-
gested that this elevation occurs mainly during the active stage
of the disease in the case of ocular involvement and in acute
thrombosis. On the other hand Erdem et al. [30] demonstrated
that the levels of serum VEGF were similar in both active and
inactive BD patients.ss (cc-IMT) and serum vascular endothelial growth factor (VEGF)
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inﬂammatory process and angiogenesis and suggested that
there is codependence between chronic inﬂammation and
angiogenesis both are a recognized stimulus for production
of VEGF and contribute to the pathophysiology of BD.
Common carotid intima media thickness is a widely ac-
cepted marker key event of subclinical atherosclerosis [14].
We found a signiﬁcant increase of cc-IMT in BD patients com-
pared to healthy controls (p= 0.011). These results are consis-
tent with previous reports [31,9,32,14]. Contrary to these
results Rhee et al. [33] found insigniﬁcant differences in cc-
IMT values between BD patients and control subjects and they
did not ﬁnd any carotid plaques in BD patients or control sub-
jects. However, they reported that BD patients have signiﬁ-
cantly increased arterial stiffness when compared to controls
that suggest carotid artery endothelial function impairment.
Tyrrell et al. [34] explained the importance of cc-IMT as fol-
lows: for an absolute carotid IMT difference of 0.1 mm the fu-
ture risk of myocardial infarction increases by 10–15% and the
stroke risk increases by 13–18%.
This study revealed a signiﬁcant increase of cc-IMT in BD
patients with ocular lesions (p< 0.001) and vascular lesions
(p< 0.001) while there was an insigniﬁcant increase of cc-
IMT in patients with arthritis (p= 0.49). These results are
consistent with those of Hong et al. [14] who found cc-IMT in-
creased in BD patients with posterior uveitis or retinal vascu-
litis and with Alan et al. [31] who revealed a signiﬁcant increase
in cc-IMT in BD patients with vascular involvement. Hassan
et al. [35] in their study on Egyptian BD patients found no sig-
niﬁcant difference when compared to the cc-IMT of these pa-
tients with regard to the presence and absence of arthritis
along with the involvement of ocular lesions.
The present study revealed a signiﬁcant correlation between
cc-IMT and age, disease duration, systolic BP, diastolic BP, to-
tal cholesterol and LDL which are known factors to promote
atherogenesis. Our results were in agreement with those of Ke-
ser et al. [9] who found that cc-IMT in BD patients correlated
with age and disease duration. Hong et al. [14] found cc-IMT
to be signiﬁcantly correlated with age. Also Caliskan et al. [36]
observed correlation between cc-IMT and age, disease dura-
tion, triglycerides and LDL cholesterol values. In addition
Rhee et al. [31] in their study on Korean BD patients noted
a positive relationship between age and cc-IMT.
Sherer and Shoenfeld [37] stated that endothelial cell dys-
function occurs early in atherosclerosis and results from oxida-
tion of low density lipoprotein cholesterol. Bacon and his
associates [38] reported that endothelial cell dysfunction corre-
lated with CRP and that CRP can predict future coronary
events. However we did not ﬁnd correlations of cc-IMT with
CRP or ESR that was in accordance to the results of Keser
et al. and Hong et al. [9,14].
In the present study there was statistically insigniﬁcant cor-
relation between cc-IMT and BDCAF. These results are con-
sistent with those of Hong et al. [14]. However, Hassan et al.
[35] revealed a signiﬁcant correlation between the BDCAF
and cc-IMT in BD patients.
We found atheromatous plaques in 4.3% of BD with an
insigniﬁcant increase of this frequency in comparison to the
control group (p= 0.243). This result was in agreement with
a previous study [39]. Contrarily, Keser et al. [9] found that
the plaque frequency in BD patients was signiﬁcantly higher
than in healthy controls. This incongruity could be explainedby differences in some related factors such as gender, BMI,
medications, blood pressure and lipids which can potentially
affect atherosclerotic plaques formation.
In the present study we found an insigniﬁcant correlation
between cc-IMT and VEGF serum levels in BD patients
(p= 0.107). O¨ztu¨rk et al. [8] found an insigniﬁcant correlation
between cc-IMT and VEGF levels neither in BD patients nor in
healthy controls and suggested that VEGF elevation may be a
feature of the inﬂammatory reaction during the course of BD.
In conclusion, BD patients have ultrasonographic evidence
of subclinical atherosclerosis which was associated with
increasing age, longer disease duration, elevated systolic and
diastolic BP, total cholesterol and LDL. Elevated VEGF
showed statistically signiﬁcant positive correlations with
BDCAF and thus can be used as a marker of disease activity
and/or therapeutic targets in BD patients.Conﬂict of interest
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